Integrative cancer pharmacogenomics to infer large-scale drug taxonomy

Cancer Research

Volumn 77, Issue 11, 2017, Pages 3057-3069

  El Hachem, Nehme ^a,b   Gendoo, Deena M A ^c,d   Ghoraie, Laleh Soltan ^c,d   Safikhani, Zhaleh ^c,d   Smirnov, Petr ^c   Chung, Christina ^e   Deng, Kenan ^e   Fang, Ailsa ^e   Birkwood, Erin ^f   Ho, Chantal ^e   Isserlin, Ruth ^e   Bader, Gary D ^d,e,g   Goldenberg, Anna ^e,h   Haibe Kains, Benjamin ^c,d,e,i  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CHEMOSENSITIVITY; CLASSIFICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; PHARMACOGENOMICS; PRIORITY JOURNAL; TAXONOMY; DRUG DELIVERY SYSTEM; HUMAN; NEOPLASMS; PHARMACOGENETICS; PROCEDURES;

CLASSIFICATION; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHARMACOGENETICS;

EID: 85020811154     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-0096     Document Type: Article

References (53)

1. Chen B, Butte AJ. Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther 2016;99:285-97.
2. Sheridan RP, Kearsley SK. Why do we need so many chemical similarity search methods? Drug Discov Today 2002;7:903-11.
3. Dunkel M, Günther S, Ahmed J, Wittig B, Preissner R. SuperPred: drug classification and target prediction. Nucleic Acids Res 2008;36:W55-9.
4. Martin YC, Kofron JL, Traphagen LM. Do structurally similar molecules have similar biological activity? J Med Chem 2002;45:4350-8.
5. Khan SA, Virtanen S, Kallioniemi OP, Wennerberg K, Poso A, Kaski S. Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. Bioinformatics 2014;30:i497-504.
6. Chen B, Greenside P, Paik H, Sirota M, Hadley D, Butte AJ. Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds. CPT Pharmacometrics Syst Pharmacol 2015;4:576-84.
7. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 2010;107:14621-6.
8. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. Drug-induced regulation of target expression. PLoS Comput Biol. 2010;6:e1000925.
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
10. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008;321:263-6.
11. Kuhn M, Al Banchaabouchi M, Campillos M, Jensen LJ, Gross C, Gavin A-C, et al. Systematic identification of proteins that elicit drug side effects. Mol Syst Biol 2013;9:663.
12. Napolitano F, Zhao Y, Moreira VM, Tagliaferri R, Kere J, D'Amato M, et al. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013;5:30.
13. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
14. Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015;5:1210-23.
15. Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014;11:333-7.
16. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 2009;10:277-277.
17. NIH and Broad Institute. The LINCS Connectivity Map Project [Internet]; 2015. Available from: https://clue.io/.
18. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res 2016;44:D1202-13.
19. Tanimoto TT. An elementary mathematical theory of classification and prediction. New York, NY: International Business Machines Corporation; 1958.
20. Guha R. Chemical informatics functionality in R. J Stat Softw 2007;18:1-16.
21. Smirnov P, Safikhani Z, El-Hachem N, Wang D, She A, Olsen C, et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics. 2015;32:1244-6.
22. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-6.
23. Nahler G.Anatomical therapeutic chemical classification system (ATC). In: Nahler G, editor. Dictionary of pharmaceutical medicine. Vienna, Austria: Springer; 2009. p.8.
24. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res 2014;42:D1083-90.
25. Cheng J, Xie Q, Kumar V, Hurle M, Freudenberg JM, Yang L, et al. Evaluation of analytical methods for connectivity map data. Pac Symp Biocomput 2013;18r:5-16. http://www.worldscientific.com/doi/abs/10.1142/9789814447973-0002
26. Schröder MS, Culhane AC, Quackenbush J, Haibe-Kains B. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 2011;27:3206-8.
27. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
28. Franz M, Lopes CT, Huck G, Dong Y, Sumer O, Bader GD. Cytoscape.js: a graph theory library for visualisation and analysis. Bioinformatics 2016;32:309-11.
29. Sandve GK, Nekrutenko A, Taylor J, Hovig E. Ten simple rules for reproducible computational research. PLoS Comput Biol 2013;9:e1003285.
30. Frey BJ, Dueck D. Clustering by passing messages between data points. Science 2007;315:972-6.
31. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008;68:6145-53.
32. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008;74:476-84.
33. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, et al. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:1864-70.
34. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004;10:6512-21.
35. Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LEC, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008;68:6669-79.
36. Ma L, Wang R, Nan Y, Li W, Wang Q, Jin F. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases. Int J Oncol 2016;48:843-53.
37. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73:3087-96.
38. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 2016;12:109-16.
39. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJS, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030-9.
40. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12:622-33.
41. Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, et al. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase P1-1. Clin Cancer Res 2012;18:6690-701.
42. Ma'ayan A, Rouillard AD, Clark NR, Wang Z, Duan Q, Kou Y. Lean Big Data integration in systems biology and systems pharmacology. Trends Pharmacol Sci 2014;35:450-60.
43. Yuan Q, Gao J, Wu D, Zhang S, Mamitsuka H, Zhu S. DrugE-Rank: improving drug-target interaction prediction of new candidate drugs or targets by ensemble learning to rank. Bioinformatics 2016;32:i18-27.
44. Antolin AA, Workman P, Mestres J, Al-Lazikani B. Polypharmacology in precision oncology: current applications and future prospects. Curr Pharm Des 2016;22:6935-45.
45. Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015;5:1210-23.
46. Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 2014;42:W449-60.
47. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell 2016;166:740-54.
48. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
49. Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 2016;533:333-7.
50. Vis DJ, Bombardelli L, Lightfoot H, Iorio F, Garnett MJ, Wessels LF. Multilevel models improve precision and speed of IC50 estimates. Pharmacogenomics 2016;17:691-700.
51. Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, et al. Revisiting inconsistency in large pharmacogenomic studies. F1000Res 2016;5:2333.
52. Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 2015;528:84-7.
53. Safikhani Z, El-Hachem N, Smirnov P, Freeman M, Goldenberg A, Birkbak NJ, et al. Consistency in drug response profiling: reply. Nature 2016;540:E6-8.